RxDoctor Payments Data

Ruel Garcia, MD

Pulmonary Disease · Orlando, FLNPI 1629170857

Payments from drug & device makers

$11,221in general payments, 2019–2025

Across 203 payments — averaging $55.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$8K
  • GSK$664
  • Sanofi$362
  • Philips North America LLC$352
  • Boehringer Ingelheim$349
  • AstraZeneca$344
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$3,52195%
  • Education$1735%
  • Gifts$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,221 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$409,628
Medicare patients
1,514
Services billed
4,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orenitram ErTreprostinil Diolamine60$798,451
UptraviSelexipag34$733,575
OfevNintedanib Esylate50$596,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter557$557,149
AdempasRiociguat36$502,302
XolairOmalizumab71$289,672
OpsumitMacitentan17$218,178
LetairisAmbrisentan14$181,053
Dupixent PenDupilumab43$174,024
Ambrisentan45$106,164
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$82,142
Fasenra PenBenralizumab11$62,080
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$57,760
Pirfenidone13$57,179
Breo ElliptaFluticasone/Vilanterol82$51,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$193$951,75351 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$664$691,520783 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$349$660,175118 claims
BayerAdempas$173$502,30236 claims
GileadLetairis$46$181,05314 claims
AstraZenecaBreztri Aerosphere, Symbicort$344$131,069236 claims
PfizerEliquis$15$13,22624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →